Use of epoetin in chronic renal failure.

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Journal of the American Medical Association (JAMA)

• Publication date

  2007-04-18

• Fields of study

  Medicine

• Identifiers
  DOI 10.1001/JAMA.297.15.1713PMID 17440149
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Translating guidelines into policy.

  2007cited by this paper
• Dialysis facility ownership and epoetin dosing in patients receiving hemodialysis.

  2007cited by this paper
• Stacking the deck.

  2007cited by this paper
• Guidance for guidelines.

  2007cited by this paper
• Comments on the guideline debate.

  2007cited by this paper
• Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis.

  2007cited by this paper
• Correction of anemia with epoetin alfa in chronic kidney disease.

  2006cited by this paper
• Appraisal of evidence and control of bias in the kidney disease outcomes quality initiative guideline development process.

  2006cited by this paper
• Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients.

  2006cited by this paper
• Annual Report for 2005

  2006cited by this paper
• Normalization of hemoglobin level in patients with chronic kidney disease and anemia.

  2006cited by this paper
• KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease.

  2006cited by this paper
• Influence of industry on renal guideline development.

  2006cited by this paper
• Practice recommendations based on low, very low, and missing evidence.

  2006cited by this paper
• Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease.

  2005cited by this paper
• Anemia management protocols: providing consistent hemoglobin outcomes.

  2005cited by this paper
• Anemia management for hemodialysis patients: Kidney Disease Outcomes Quality Initiative (K/DOQI) guidelines and Dialysis Outcomes and Practice Patterns Study (DOPPS) findings.

  2004cited by this paper
• Epoetin requirements predict mortality in hemodialysis patients.

  2004cited by this paper
• Death, hospitalization, and economic associations among incident hemodialysis patients with hematocrit values of 36 to 39%.

  2001cited by this paper
• The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin.

  1998cited by this paper

• Indoxyl sulfate impairs erythropoiesis at BFU-E stage in chronic kidney disease.

  2022cites this paper
• Uremic Toxins Affect Erythropoiesis during the Course of Chronic Kidney Disease: A Review

  2020cites this paper
• Neocytolysis in Hemodialysis Patients : Effects of Erythropoietin Treatment and Withdrawal

  2017cites this paper
• Impact of the End Stage Renal Disease Prospective Payment System on the Use of Peritoneal Dialysis

  2016cites this paper
• Anemia in Chronic Kidney Disease: Treating the Numbers, Not the Patients

  2014cites this paper
• The landscape of clinical trials in nephrology: a systematic review of Clinicaltrials.gov.

  2014cites this paper
• Blood pressure increase after erythropoietin injection in hemodialysis and predialysis patients.

  2013cites this paper
• Changing patterns of anemia management in US hemodialysis patients.

  2012cites this paper
• Mortality Associated with Dose Response of Erythropoiesis-Stimulating Agents in Hemodialysis versus Peritoneal Dialysis Patients

  2012cites this paper
• Conflicts of interest in cardiovascular clinical practice guidelines.

  2011cites this paper
• Trial quality in nephrology: how are we measuring up?

  2011cites this paper
• Peritoneal dialysis first: rationale.

  2011cites this paper
• The future of intravenous iron in nephrology

  2011cites this paper
• Peritoneal Dialysis First: Rationale In-Depth Review

  2011cites this paper
• Do Resource Utilization and Clinical Measures Still Vary Across Dialysis Chains After Controlling for the Local Practices of Facilities and Physicians?

  2010cites this paper
• Recombinant human erythropoietin therapy in predialysis patients of chronic kidney disease

  2010cites this paper
• Predictors of hyporesponsiveness to erythropoiesis-stimulating agents in hemodialysis patients.

  2009cites this paper
• Association of quarterly average achieved hematocrit with mortality in dialysis patients: a time-dependent comorbidity-adjusted model.

  2009cites this paper
• Hemoglobin variability in anemia of chronic kidney disease.

  2009cites this paper
• [Hemoglobin targets in anemic patients with chronic kidney disease treated with erythropoietin].

  2008cites this paper
• Érythropoïétine et insuffisance rénale : jusqu’où ne pas aller ?

  2008cites this paper
• Zum optimalen Hämoglobinzielbereich bei renaler Anämie

  2008cites this paper
• Too much of a good thing

  2007cites this paper
• Dialysis Facility Ownership and Epoetin Dosing in Hemodialysis Patients: A Dialysis Provider's Perspective

  2007cites this paper
• Epoetin dosing and dialysis facility ownership.

  2007cites this paper
• Dialysis facility ownership and epoetin dosing in patients receiving hemodialysis: the authors respond.

  2007cites this paper
• Dialysis facility ownership and epoetin dosing in hemodialysis patients: a medical economic perspective.

  2007cites this paper
• Chronic kidney disease and the public health: gaps in evidence from interventional trials.

  2007cites this paper
• Dialysis facility ownership and epoetin dosing in hemodialysis patients: an overview.

  2007cites this paper
• Epoetin dosing and dialysis facility ownership.

  2007cites this paper
• Dialysis facility ownership and epoetin dosing in hemodialysis patients: a US physician perspective.

  2007cites this paper
• Hemoglobin variability and mortality in ESRD.

  2007cites this paper
• Dialysis facility ownership and epoetin dosing in hemodialysis patients: a dialysis provider's perspective.

  2007cites this paper